Physicochemical Properties
| Molecular Formula | C24H32O6 |
| Molecular Weight | 416.514 |
| Exact Mass | 416.219 |
| CAS # | 61281-38-7 |
| Related CAS # | Schisandrin;7432-28-2 |
| PubChem CID | 155256 |
| Appearance | White to off-white solid powder |
| Density | 1.1±0.1 g/cm3 |
| Boiling Point | 544.2±50.0 °C at 760 mmHg |
| Melting Point | 114 °C |
| Flash Point | 215.6±30.0 °C |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.520 |
| LogP | 5.87 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 30 |
| Complexity | 484 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | O(C([H])([H])[H])C1C(=C(C([H])=C2C=1C1=C(C(=C(C([H])=C1C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C2([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H] |
| InChi Key | JEJFTTRHGBKKEI-OKILXGFUSA-N |
| InChi Code | InChI=1S/C24H32O6/c1-13-9-15-11-17(25-3)21(27-5)23(29-7)19(15)20-16(10-14(13)2)12-18(26-4)22(28-6)24(20)30-8/h11-14H,9-10H2,1-8H3/t13-,14+ |
| Chemical Name | (9S,10R)-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaene |
| Synonyms | Deoxyschizandrin Schizandrin A Deoxyschisandrin |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | With an IC50 of 6.60 μM, schisandrin A (Sch A) potently inhibits the microsomal midazolam 1-hydroxylation process mediated by CYP3A. The dilution assay graph displays the recovery of enzyme activity in the presence and absence of Schisandrin A. Using the Dixon plot, the Ki value of Schisandrin A was found to be 5.83 μM. The research discovered that Schisandrin A deactivated the midazolam 1-hydroxylation activity of rat liver microsomes in a concentration- and time-dependent manner when NADPH was present. Schisandrin A's kappa and Ki are calculated to be 4.51 μM and 0.134/min, respectively [1]. |
| ln Vivo | In a concentration-dependent manner, schisandrin A (SchA) markedly reduced the CYP3A activity of rat liver microsomes as well as the Vmax value of every group. Schisandrin A suppresses CYP3A activity, as seen by the double reciprocal plot and the quadratic plot, with an apparent Ki value of 30.67 mg/kg. When compared to the Negative group, Schisandrin A also dramatically decreased the plasma concentrations of 1-hydroxymidazolam in each Schisandrin A treatment group, bringing them down to levels comparable to those in the Positive group [2]. |
| References |
[1]. Inhibitory effects of Schisandrin A and Schisandrin B on CYP3A activity. Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):163-9. [2]. Inhibitory effects of continuous ingestion of Schisandrin A on CYP3A in the rat. Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):187-92. |
| Additional Infomation |
Schizandrin A is a tannin. Schizandrin A has been reported in Schisandra bicolor, Schisandra sphenanthera, and other organisms with data available. See also: Schisandra chinensis fruit (part of); Deoxyschizandrin (annotation moved to). |
Solubility Data
| Solubility (In Vitro) | DMSO : ~50 mg/mL (~120.05 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.00 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4009 mL | 12.0045 mL | 24.0090 mL | |
| 5 mM | 0.4802 mL | 2.4009 mL | 4.8018 mL | |
| 10 mM | 0.2401 mL | 1.2005 mL | 2.4009 mL |